Gabriela Elisa Mercado-Celis

Dr. Gabriela Elisa Mercado-Celis


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2014 in Periodontology 2000
Verified
Journal Article
Closed access
PDF file
HAHiginio Arzate
Higinio Arzate
MZMargarita Zeichner‐David
Margarita Zeichner‐David
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis

1 February 2007 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis
FBFrederic G. Barr
Frederic G. Barr
Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric population. Two main histopathologic variants have been described, embryonal (ERMS) and alveolar (ARMS), which demonstrate clinical and genetic differences. In particular, most ARMS but not ERMS tumors are characterized by the presence of recurrent chromosomal translocations, which have been cytogenetically defined as t(2;13)(q35;q14) and t(1;13)(p36;q14). These translocations form PAX3- FKHR and PAX7-FKHR gene fusions, which encode chimeric transcription factors. These chimeric proteins are hypothesized to generate a novel transcriptional program in the target cell, thereby contributing to multiple aspects of ARMS tumorigenesis. This review highlights recent advances in numerous areas of biomedical investigation that are providing new insights into the biology, molecular pathology, and translational science of ARMS: the identification of downstream targets of PAX3-FKHR and collaborating events in the process of tumorigenesis and metastasis; generation of animal models based on the gene fusion and collaborating events; development of new assays for diagnosis, prognosis, and detection of minimal disseminated disease; and exploration of immune recognition of this tumor and the fusion protein. These findings highlight the continued importance of the fusion proteins in understanding the biology of this tumor and developing improved diagnostics for this tumor, and have led to the initiation of efforts to explore therapeutic strategies based on the increasing understanding of the biology of these fusion proteins.

19 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JMJorge Melendez-Zajgla
Jorge Melendez-Zajgla
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis
JGJavier Gaytan-Cervantes
Javier Gaytan-Cervantes
ATAmada Torres
Amada Torres
NGNayeli Belem Gabiño
Nayeli Belem Gabiño
EMElvia Mendoza-Caamal
Elvia Mendoza-Caamal
Ovarian fibrosarcomas are extremely rare tumors with little genomic information available to date. In the present report we present the tumoral exome and transcriptome and the germinal exome of an ovarian fibrosarcoma from a 9-years old child. We found a paucity of mutations (0.77/Mb) and CNV alterations. Of these, the most relevant were a point mutation in the metal-binding site of the microRNA-processing DICER1 enzyme and a frame-shift alteration in the tumor suppressor gene NF1. We validated a germinal truncating mutation in DICER1, which was consistent with a DICER1 Syndrome diagnosis, providing the first example of an ovarian fibrosarcoma as the presenting neoplasia in this syndrome. Network and enrichment analyses showed that both a mesenchymal signature and a Hedgehog cascade could be driving the progression of this tumor. We were also able to find a global lincRNA deregulation, as the number of lincRNAs transcripts expressed in the tumor was decreased, with a concomitant upregulation of previously described non-coding transcripts associated with cancer, such as MALAT1, MIR181A1HG, CASC1, XIST and FENDRR. DICER1 Syndrome should be considered as a possible diagnosis in children ovarian fibrosarcoma. The role of lncRNAs in neoplasias associated with DICER1 alterations need to be studied in more detail.

9 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAshwini S. Kamath-Loeb
Ashwini S. Kamath-Loeb
DRDiego G. Zavala-Van Rankin
Diego G. Zavala-Van Rankin
JFJeny Flores-Morales
Jeny Flores-Morales
MEMary J. Emond
Mary J. Emond
JSJulia M. Sidorova
Julia M. Sidorova
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis
Loss-of-function mutations in theWRNhelicase gene cause Werner syndrome- a progeroid syndrome with an elevated risk of cancer and other age-associated diseases. Large numbers of single nucleotide polymorphisms have been identified inWRN. We report here the organismal, cellular, and molecular phenotypes of variant rs3087425 (c. 2500C > T) that results in an arginine to cysteine substitution at residue 834 (R834C) and up to 90% reduction of WRN helicase activity. This variant is present at a high (5%) frequency in Mexico, where we identified 153 heterozygous and three homozygous individuals among 3,130 genotyped subjects. Family studies of probands identified ten additional TT homozygotes. Biochemical analysis of WRN protein purified from TT lymphoblast cell lines confirmed that the R834C substitution strongly and selectively reduces WRN helicase, but not exonuclease activity. Replication track analyses showed reduced replication fork progression in some homozygous cells following DNA replication stress. Among the thirteen TT homozygotes, we identified a previously unreported and statistically significant gender bias in favor of males (p = 0.0016), but none of the clinical findings associated with Werner syndrome. Our results indicate that WRN helicase activity alone is not rate-limiting for the development of clinical WS.

29 December 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
DVDavid Velázquez-Fernández
David Velázquez-Fernández
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis
JFJeny Flores-Morales
Jeny Flores-Morales
DCDiana Clavellina-Gaytán
Diana Clavellina-Gaytán
RVRamón Vidrio
Ramón Vidrio
MHMiguel F. Herrera
Miguel F. Herrera

3 June 2013 in Oncology Reports
Verified
Journal Article
Open access
PDF file
EAEun Hyun Ahn
Eun Hyun Ahn
GMGabriela Elisa Mercado-Celis
Gabriela Elisa Mercado-Celis
MLMarick Laé
Marick Laé
MLMarc Ladanyi
Marc Ladanyi
Rhabdomyosarcoma (RMS) is a soft tissue sarcoma categorized into two major subtypes: alveolar RMS (ARMS) and embryonal RMS (ERMS). Most ARMS express the PAX3-FOXO1 (P3F) fusion oncoprotein generated by the 2;13 chromosomal translocation. In the present study, the downstream target genes of P3F were identified by analyzing two independent sets of gene expression profiles: primary RMS tumors and RD ERMS cells transduced with inducible P3F constructs. We found 34 potential target genes (27 upregulated and 7 downregulated) that were significantly and differentially expressed between P3F-positive and P3F-negative categories, both in primary RMS tumors and in the inducible P3F cell culture system. Gene ontology analysis of microarray data of the inducible P3F cell culture system employed indicated apoptosis, cell death, development, and signal transduction as overrepresented significant functional categories found in both upregulated and downregulated genes. Therefore, among the 34 potential target genes, the expression of cell death‑related [Gremlin1, cysteine knot superfamily 1, BMP antagonist 1 (GREM1) and death-associated protein kinase 1 (DAPK1)] and development‑related [myogenic differentiation 1 (MYOD1) and hairy/enhancer-of-split related with YRPW motif 1 (HEY1)] genes were further investigated. The differential expression of GREM1, DAPK1, MYOD1 and HEY1 was confirmed in independent tumors and inducible cell culture systems. The expression of GREM1, DAPK1 and MYOD1 were significantly upregulated; HEY1 was significantly downregulated in independent P3F-positive ARMS tumors and transcriptionally active P3F cells, compared to those in ERMS tumors and transcriptionally inactive P3F cells. This study identified target genes of P3F and suggested that four downstream targets (GREM1, DAPK1, MYOD1 and HEY1) can contribute to the biological activities of P3F involved in growth suppression or cell death and myogenic differentiation.